Boston Scientific develops, manufactures, and markets medical devices. Q4 earnings were reported this week providing a clear picture of 2022 annual fundamentals. The fundamentals considered are presented on the chart with brief commentary.
Technical considerations:
Price bounced off of trend line going back to 2012
Ascending triangle breakout
New ATH weekly close
Positions:
Entry: 100 shares @ $48.71
Target: $67.43 by July 2025
Stop: $44.19 (~20-week SMA, below 2023 low)
R/R: 4.14
Reward: $1872
Risk: $452
Time Horizon: 12+ months
Current price (weekly close): $48.50
Risk Analysis Chart:
Main chart before distorted by publishing process:
Technical considerations:
Price bounced off of trend line going back to 2012
Ascending triangle breakout
New ATH weekly close
Positions:
Entry: 100 shares @ $48.71
Target: $67.43 by July 2025
Stop: $44.19 (~20-week SMA, below 2023 low)
R/R: 4.14
Reward: $1872
Risk: $452
Time Horizon: 12+ months
Current price (weekly close): $48.50
Risk Analysis Chart:
Main chart before distorted by publishing process:
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.